Dr. Liu has over 20 years’ experience in biological drug development. Before he co-founded Shenzhen Enduring, he worked for Bristol-Myers Squibb to lead Clinical Manufacturing Activities, responsible for the GMP production and IND application of phase I-II clinical monoclonal antibodies. Before that, he worked for Belrose Pharma and Enzon Pharmaceuticals, INC. as a senior scientist. He is an expert in developing biological drugs, especially in developing PEGylated biological drugs. Under his leadership, two PEGylated protein drugs were approved by FDA during his 13-year tenure in Enzon pharmaceuticals, INC. Dr. Liu received his Ph.D from Penn State University in US.
0.00
0.00
Sam Liu (Ph.D), CEO and co-founder.
Dr. Liu has over 20 years’ experience in biological drug development. Before he co-founded Shenzhen Enduring, he worked for Bristol-Myers Squibb to lead Clinical Manufacturing Activities, responsible for the GMP production and IND application of phase I-II clinical monoclonal antibodies. Before that, he worked for Belrose Pharma and Enzon Pharmaceuticals, INC. as a senior scientist. He is an expert in developing biological drugs, especially in developing PEGylated biological drugs. Under his leadership, two PEGylated protein drugs were approved by FDA during his 13-year tenure in Enzon pharmaceuticals, INC. Dr. Liu received his Ph.D from Penn State University in US.